Real-world effectiveness of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler on symptoms and quality of life in patients with COPD: EBISU study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Triple therapy with budesonide/glycopyrronium/formoterol fumarate (BGF) metered dose inhaler (MDI) significantly improved symptoms and health status in COPD patients. This real-world study shows BGF MDI is effective for managing persistent COPD symptoms without asthma.
Area Of Science
- Respiratory Medicine
- Clinical Pharmacology
Background
- Limited real-world data exist for triple therapy (inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist) in COPD patients without asthma.
- Investigated budesonide/glycopyrronium/formoterol fumarate (BGF) metered dose inhaler (MDI) triple therapy's impact on health status and patient-reported outcomes (PROs) in a real-world COPD population.
Purpose Of The Study
- To evaluate the effectiveness of BGF MDI triple therapy on COPD symptoms and patient-reported outcomes in a real-world clinical setting.
- To assess changes in COPD Assessment Test (CAT) and St George's Respiratory Questionnaire (SGRQ) scores over 12 weeks.
Main Methods
- A 12-week, prospective, multicenter, observational study (ClinicalTrials.gov: NCT05219630).
- Primary endpoint: Mean change from baseline in CAT score.
- Secondary endpoints: Mean change from baseline in SGRQ score and CAT score subgroup analyses.
Main Results
- 102 COPD patients analyzed (mean age 73.8 years, FEV1 57.7%).
- Significant improvement in adjusted mean CAT score (-2.9, P < 0.001) and SGRQ score (-2.7, P = 0.004) from baseline over 12 weeks.
- Improvements observed as early as Week 4 and were consistent across subgroups regardless of blood eosinophil counts or prior exacerbation history.
Conclusions
- BGF MDI triple therapy demonstrated significant improvements in CAT and SGRQ scores over 12 weeks in COPD patients.
- BGF MDI is a viable treatment option for COPD patients with persistent symptoms, even without a history of asthma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Primary Step: The most critical intervention for all COPD patients who smoke.
Benefits: Slows disease...
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
• Symptom Review: Chronic symptoms such as persistent cough, sputum production, shortness of breath (dyspnea), and episodes of exacerbation are...
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...